Back to Trades
Khan Najat
CEO and PresidentDirectorCIK 0002020969
Largest Purchase
No open-market purchases in the recent filings.
Profile
- Filings
- 8
- Buy transactions
- 0
- Sell transactions
- 3
- Companies
- 1
- Active
- 2025–2026
Khan Najat, CEO and President, Director, has filed 8 reports across 1 company, totaling $2.1M in disclosed volume. Sales ($835.2K) outpace purchases ($0). Insider sales are common for diversification and should be read in context. All data sourced from SEC Form 3, 4, and 5 filings.
Associated Companies
Trading History
8 loaded
| Jun 5 | RXRX RECURSION PHARMACEUTICALS, INC. | Khan Najat | CEO and President, Director | Sell | $84.5K |
| May 19 | RXRX RECURSION PHARMACEUTICALS, INC. | Khan Najat | CEO and President, Director | Other | $0 |
| Feb 19 | RXRX RECURSION PHARMACEUTICALS, INC. | Khan Najat | CEO and President, Director | Other | $0 |
| Feb 10 | RXRX RECURSION PHARMACEUTICALS, INC. | Khan Najat | CEO and President, Director | Grant | $0 |
| Dec 29 | RXRX RECURSION PHARMACEUTICALS, INC. | Khan Najat | Chief R&D Commercial Officer, Director | Sell | $548.6K |
| Nov 19 | RXRX RECURSION PHARMACEUTICALS, INC. | Khan Najat | Chief R&D Commercial Officer, Director | Other | $0 |
| Nov 6 | RXRX RECURSION PHARMACEUTICALS, INC. | Khan Najat | Chief R&D Commercial Officer, Director | Grant | $0 |
| Aug 19 | RXRX RECURSION PHARMACEUTICALS, INC. | Khan Najat | Chief R&D Commercial Officer, Director | Sell | $202.2K |
8 filings